Vaupel P, Kelleher DK, Hockel M: Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001, 28:29–35. ArticlePubMedCAS Google Scholar
Vaupel P, Mayer A, Briest S, Hockel M: Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol 2005, 566:333–342. ArticlePubMed Google Scholar
Jain RK: Determinants of tumor blood flow: a review. Cancer Res 1988, 48:2641–2658. PubMedCAS Google Scholar
Maruyama K, Ishida O, Takizawa T, Moribe K: Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev 1999, 40:89–102. ArticlePubMedCAS Google Scholar
Braun RD, Abbas A, Bukhari SO, Wilson W III: Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid. Invest Ophthalmol Vis Sci 2002, 43:3045–3052. PubMed Google Scholar
Al-Rawi MA, Mansel RE, Jiang WG: Lymphangiogenesis and its role in cancer. Histol Histopathol 2005, 20:283–298. PubMedCAS Google Scholar
Grantab R, Sivananthan S, Tannock IF: The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res 2006, 66:1033–1039. ArticlePubMedCAS Google Scholar
Jain RK: Transport of macromolecules in the tumor interstitium: a review. Cancer Res 1987, 47:3039–3051. PubMedCAS Google Scholar
Toole BP: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004, 4:528–539. ArticlePubMedCAS Google Scholar
Nederman T, Carlsson J: Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids. Cancer Chemother Pharmacol 1984, 13:131–135. ArticlePubMedCAS Google Scholar
Erlanson M, Daniel-Szolgay E, Carlsson J: Relations between the penetration, binding and average concentration of cytostatic drugs in human tumour spheroids. Cancer Chemother Pharmacol 1992, 29:343–353. ArticlePubMedCAS Google Scholar
Kuh H-J, Jang SH, Guillaume Wientjes M, et al.: Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exp Ther 1999, 290:871–880. PubMedCAS Google Scholar
Jang SH, Guillaume Wientjes M, Au JL-S: Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther 2001, 296:1035–1042. PubMedCAS Google Scholar
Svastova E, Hulikova A, Rafajova M, et al.: Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004, 577:439–435. ArticlePubMedCAS Google Scholar
Wike-Hooley JL, Haveman J, Reinhold HS: The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984, 2:343–366. ArticlePubMedCAS Google Scholar
Madshus IH: Regulation of intracellular pH in eukaryotic cells. Biochem J 1988, 250:1–8. PubMedCAS Google Scholar
Mahoney BP, Raghunand N, Baggett B, Gillies RJ: Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 2003, 66:1207–1218. ArticlePubMedCAS Google Scholar
Vukovic V, Tannock IF: Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 1997, 75:1167–1172. PubMedCAS Google Scholar
Acker T, Plate KH: Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 2004, 117:219–248. PubMedCAS Google Scholar
Hussein D, Estlin EJ, Dive C, Makin GW: Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 2006, 5:2241–2250. ArticlePubMedCAS Google Scholar
Krishnamurthy P, Schuetz JD: The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival. Biometals 2005, 18:349–358. ArticlePubMedCAS Google Scholar
Krishnamurthy P, Schuetz JD: Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol. 2006, 46:381–410. ArticlePubMedCAS Google Scholar
Burger H, van Tol H, Brok M, et al.: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 2005, 4:747–752. ArticlePubMedCAS Google Scholar
Calatozzolo C, Gelati M, Ciusani E, et al.: Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005, 74:113–121. ArticlePubMedCAS Google Scholar
Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A: Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005, 16:691–707. ArticlePubMedCAS Google Scholar
Yih TC, Al-Fandi M: Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 2006; 97:1184–1190. ArticlePubMedCAS Google Scholar
Drummond DC, Meyer O, Hong K, et al.: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999, 51:691–743. PubMedCAS Google Scholar
Northfelt DW, Martin FJ, Working P, et al.: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi’s sarcoma. J Clin Pharmacol 1996, 36:55–63. PubMedCAS Google Scholar
Kontermann RE: Immunoliposomes for cancer therapy. Curr Opin Mol Ther 2006, 8:39–45. PubMedCAS Google Scholar
Gao Z, Fain HD, Rapoport N: Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol Pharm 2004, 1:317–330. ArticlePubMedCAS Google Scholar
Wu AM, Senter PD: Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005, 23:1137–1146. ArticlePubMedCAS Google Scholar
Ahmed M, Goldberg SN: Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 2004, 20:781–802. ArticlePubMedCAS Google Scholar
Zheng JH, Chen CT, Au JL, Wientjes MG: Time-and concentration-dependent penetration of doxorubicin in prostate tumors. AAPS PharmSci 2001, 3:E15. ArticlePubMedCAS Google Scholar
Eikenes L, Tari M, Tufto I, et al.: Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer 2005, 93:81–88. ArticlePubMedCAS Google Scholar
Hurwitz, H. Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342. ArticlePubMedCAS Google Scholar
Tong RT, Boucher Y, Kozin SV et al.: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731–3736. ArticlePubMedCAS Google Scholar
Winkler, F. Kozin SV, Tong RT, et al.: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553–563. PubMedCAS Google Scholar
Franco, M, Man S, Chen L, et al.: Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006, 66:3639–3648. ArticlePubMedCAS Google Scholar
Hirpara JL, Clement MV, Pervaiz S: Intracellular acidification triggered by mitochondrial-derived hydrogen peroxide is an effector mechanism for drug-induced apoptosis in tumor cells. J Biol Chem 2001, 276:514–521. ArticlePubMedCAS Google Scholar
Ahmad KA, Iskandar KB, Hirpara JL, et al.: Hydrogen peroxide-mediated cytosolic acidification is a signal for mitochondrial translocation of Bax during drug-induced apoptosis of tumor cells. Cancer Res 2004, 64:7867–7878. ArticlePubMedCAS Google Scholar
De Milito A, Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005, 1:779–786. ArticlePubMed Google Scholar
Stratford IJ, Williams KJ, Cowen RL, Jaffar M: Combining bioreductive drugs and radiation for the treatment of solid tumors. Semin Radiat Oncol 2003, 13:42–52. ArticlePubMed Google Scholar
Boyle RG, Travers S: Hypoxia: targeting the tumour. Anticancer Agents Med Chem 2006, 6:281–286. ArticlePubMedCAS Google Scholar
von Pawel J, von Roemeling R, Gatzemeier U, et al.: Tirazpamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 2000, 18:1351–1359. Google Scholar
Rischin D, Peters L, Hicks R, et al.: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001, 19:535–542. PubMedCAS Google Scholar
Papadopoulou MV, Bloomer WD: NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug. Clin Cancer Res 2003, 9:5714–5720. PubMedCAS Google Scholar